Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance:: A meta-analysis of randomized, controlled trials

被引:151
作者
Bliziotis, IA
Samonis, G
Vardakas, KZ
Chrysanthopoulou, S
Falagas, ME
机构
[1] Henry Dunant Hosp, Alfa Inst Biomed Sci, Athens, Greece
[2] Henry Dunant Hosp, Dept Med, Athens, Greece
[3] Univ Crete, Dept Med, Sch Med, Iraklion, Greece
[4] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA
关键词
D O I
10.1086/430912
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The addition of an aminoglycoside to a Beta-lactam therapy regimen has been suggested to have a beneficial effect in delaying or preventing the development of antimicrobial resistance. We studied the effect of aminoglycoside/beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of resistance. Methods. We performed a meta-analysis of randomized, controlled trials (RCTs) that compared aminoglycoside/beta-lactam combination therapy with beta-lactam monotherapy and that reported data regarding the emergence of resistance (primary outcome) and/or development of superinfection, treatment failure, treatment failure attributable to emergence of resistance, treatment failure attributable to superinfection, all-cause mortality during treatment, and mortality due to infection. Data for this meta-analysis were identified from the PubMed database, Current Contents database, Cochrane central register of controlled trials, and references in relevant articles. Results. A total of 8 RCTs were included in the analysis. beta-Lactam monotherapy was not associated with a greater emergence of resistance than was the aminoglycoside/b-lactam combination (odds ratio [OR], 0.90; 95% confidence interval [CI], 0.56 - 1.47). Actually, beta-lactam monotherapy was associated with fewer superinfections (OR, 0.62; 95% CI, 0.42 - 0.93) and fewer treatment failures (OR, 0.62; 95% CI, 0.38 - 1.01). Rates of treatment failure attributable to emergence of resistance (OR, 3.09; 95% CI, 0.75 - 12.82), treatment failure attributable to superinfection (OR, 0.60; 95% CI, 0.33 - 1.10), all-cause mortality during treatment (OR, 0.70; 95% CI, 0.40 - 1.25), and mortality due to infection (OR, 0.74; 95% CI, 0.46 - 1.21) did not differ significantly between the 2 regimens. Conclusions. Compared with b-lactam monotherapy, the aminoglycoside/beta-lactam combination was not associated with a beneficial effect on the development of antimicrobial resistance among initially antimicrobial-susceptible isolates.
引用
收藏
页码:149 / 158
页数:10
相关论文
共 85 条
  • [1] ALFORD RH, 1987, CURRENT CLIN TOPICS, P204
  • [2] Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit
    AlvarezLerma, F
    Pellus, AM
    Sanchez, BA
    Ortiz, EP
    Jorda, R
    Barcenilla, F
    Maravi, E
    Galvan, B
    Palomar, M
    Serra, J
    Bermejo, B
    Mateu, A
    Quintana, E
    Palacios, MS
    Giral, R
    Gonzalez, V
    Lerma, FA
    Mesa, JL
    Melgarejo, JA
    Martinez, J
    Insausti, J
    Olaechea, P
    Chanovas, M
    Gilabert, A
    Junquera, C
    Valles, J
    Palacios, F
    Calvo, R
    Mesalles, E
    Nava, J
    Santos, A
    Armengol, S
    Marzo, D
    [J]. INTENSIVE CARE MEDICINE, 1996, 22 (05) : 387 - 394
  • [3] Badaró Roberto, 2002, Braz J Infect Dis, V6, P206, DOI 10.1590/S1413-86702002000500001
  • [4] BERGERON MG, 1988, ANTIMICROB AGENTS CH, V32, P1321
  • [5] Biglino A, 1991, J Chemother, V3 Suppl 1, P208
  • [6] Emergence of antibiotic-resistant Pseudomonas aeruginosa:: Comparison of risks associated with different antipseudomonal agents
    Carmeli, Y
    Troillet, N
    Eliopoulos, GM
    Samore, MH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) : 1379 - 1382
  • [7] ENTEROBACTER BACTEREMIA - CLINICAL-FEATURES AND EMERGENCE OF ANTIBIOTIC-RESISTANCE DURING THERAPY
    CHOW, JW
    FINE, MJ
    SHLAES, DM
    QUINN, JP
    HOOPER, DC
    JOHNSON, MP
    RAMPHAL, R
    WAGENER, MM
    MIYASHIRO, DK
    YU, VL
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (08) : 585 - 590
  • [8] PROSPECTIVE RANDOMIZED COMPARISON OF IMIPENEM MONOTHERAPY WITH IMIPENEM PLUS NETILMICIN FOR TREATMENT OF SEVERE INFECTIONS IN NONNEUTROPENIC PATIENTS
    COMETTA, A
    BAUMGARTNER, JD
    LEW, D
    ZIMMERLI, W
    PITTET, D
    CHOPART, P
    SCHAAD, U
    HERTER, C
    EGGIMANN, P
    HUBER, O
    RICOU, B
    SUTER, P
    AUCKENTHALER, R
    CHIOLERO, R
    BILLE, J
    SCHEIDEGGER, C
    FREI, R
    GLAUSER, MP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (06) : 1309 - 1313
  • [9] CEFTAZIDIME VERSUS TOBRAMYCIN-TICARCILLIN IN THE TREATMENT OF PNEUMONIA AND BACTEREMIA
    CONE, LA
    WOODARD, DR
    STOLTZMAN, DS
    BYRD, RG
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (01) : 33 - 36
  • [10] THERAPY OF STAPHYLOCOCCAL INFECTIONS WITH CEFAMANDOLE OR VANCOMYCIN ALONE OR WITH A COMBINATION OF CEFAMANDOLE AND TOBRAMYCIN
    COPPENS, L
    HANSON, B
    KLASTERSKY, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1983, 23 (01) : 36 - 41